GlaxoSmithKline Looks to Expand Nucala Indication in the U.S.
November 19 2018 - 8:45AM
Dow Jones News
By Carlo Martuscelli
GlaxoSmithKline PLC (GSK.LN) said Monday that it is looking to
expand the indication for its Nucala medicine--an add-on treatment
for severe eosinophilic asthma--to include children aged six to 11
in the U.S.
The pharmaceutical company said that it has filed a supplemental
biologics license application with the Food and Drug administration
to expand the indication to include the lower age group.
In Europe, Nucala is available for children aged six to 17 years
old, as well as adults, GlaxoSmithKline said.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 19, 2018 08:30 ET (13:30 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024
